Recent advances in the field of anti-cancer immunotherapy, BBA clinical, vol.3, pp.280-288, 2015. ,
Antibody therapy of cancer, Nat Rev Cancer, vol.12, pp.278-87, 2012. ,
Overcome the Impairment of NK Cells for Icon and Antibody Immunotherapy of Cancer Journal of Immune Based Therapies, Vaccines and Antimicrobials, vol.2, pp.1-8, 2013. ,
Obinutuzumab: what is there to learn from clinical trials? Blood, 2017. ,
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene, Blood, vol.99, pp.754-762, 2002. ,
Glycosylation as a strategy to improve antibody-based therapeutics, Nat Rev Drug Discov, vol.8, pp.226-260, 2009. ,
Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression, Oncotarget, vol.8, pp.24031-24075, 2017. ,
NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment ,
URL : https://hal.archives-ouvertes.fr/hal-01780378
Identification of anti tumor cells carrying natural killer (NK) cell antigens in patients with hematological cancers, EBioMedicine, vol.2, pp.1364-76, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-01867114
,
, Isoform Profile Identifies Natural Killer (NK) Subsets with Differential Activity, vol.11, p.150434, 2016.
From tumor cell metabolism to tumor immune escape, Int J Biochem Cell Biol, vol.45, pp.106-119, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-00726717
Chemical metabolic inhibitors for the treatment of blood-borne cancers. Anti-cancer agents in medicinal chemistry, vol.14, pp.223-255, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-01867009
Natural Killer Cells Modulation in Hematological Malignancies, Frontiers in immunology, vol.4, p.459, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01455668
IL-1beta inhibits ILC3 while favoring NK-cell maturation of umbilical cord blood CD34(+) precursors, Eur J Immunol, vol.45, pp.2061-71, 2015. ,
Human NK cells: From surface receptors to clinical applications, Immunology letters, vol.178, pp.15-24, 2016. ,
Targeting NK-cell checkpoints for cancer immunotherapy, Curr Opin Immunol, vol.45, pp.73-81, 2017. ,
Umbilical Cord Blood Natural Killer Cells, Their Characteristics, and Potential Clinical Applications, Frontiers in immunology, vol.8, p.329, 2017. ,
Two-Stage Priming of Allogeneic Natural Killer Cells for the Treatment of Patients with Acute Myeloid Leukemia: A Phase I Trial, PLoS One, vol.10, p.123416, 2015. ,
Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies, PLoS One, vol.8, p.57922, 2013. ,
Ex vivo-expanded natural killer cells kill cancer cells more effectively than ex vivo-expanded gammadelta T cells or alphabeta T cells, International immunopharmacology, vol.22, pp.486-91, 2014. ,
Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity, Journal of experimental & clinical cancer research : CR, vol.29, p.134, 2010. ,
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy, Frontiers in immunology, vol.6, p.368, 2015. ,
All-trans retinoic acid (ATRA) induces miR-23a expression, decreases CTSC expression and granzyme B activity leading to impaired NK cell cytotoxicity, Int J Biochem Cell Biol, vol.49, pp.42-52, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-01867016
Human NK cells activated by EBV lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells, Oncoimmunology, vol.4, p.991613, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01835574
Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells, Frontiers in immunology, vol.7, p.454, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01835596
Recombinant production of human ICAM-1 chimeras by single step on column refolding and purification, Process in Biochemistry, vol.48, pp.708-723, 2013. ,
,
The presence of wild type p53 in hematological cancers improves the efficacy of combinational therapy targeting metabolism, Oncotarget, vol.6, pp.19228-19273, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-01868552
Protein kinase C-theta is required for NK cell activation and in vivo control of tumor progression, J Immunol, vol.182, pp.1972-81, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-02194087
Protein Kinase C-theta (PKC-theta) in Natural Killer Cell Function and Anti-Tumor Immunity, Frontiers in immunology, vol.3, p.187, 2012. ,
Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity, Blood, vol.119, pp.3734-3777, 2012. ,
,
, The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody, Blood, vol.116, pp.2286-94, 2010.
Signatures of human NK cell development and terminal differentiation, Frontiers in immunology, vol.4, p.57, 2013. ,
, Expression on Human NK Cells and Relevance to Disease, Frontiers in immunology, vol.4, p.422, 2013.
Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients, Clin Cancer Res, vol.22, pp.5229-5266, 2016. ,
Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia, Journal of the advanced practitioner in oncology, vol.6, pp.370-374, 2015. ,
Fas ligand and lytic granule differentially control cytotoxic dynamics of Natural Killer cell against cancer target, Oncotarget, vol.37, pp.3653-3662, 2004. ,
The multi-faceted potential of CD38 antibody targeting in multiple myeloma, Cancer Immunol Immunother, 2017. ,
High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status, Cancer Immunol Immunother, vol.66, pp.51-61, 2017. ,
The landscape of somatic copy-number alteration across human cancers, Nature, vol.463, pp.899-905, 2010. ,
Liposomes decorated with Apo2L/TRAIL overcome chemoresistance of human hematologic tumor cells, Molecular pharmaceutics, vol.10, pp.893-904, 2013. ,
Melanoma cells become resistant to NK-cell-mediated killing when exposed to NK-cell numbers compatible with NK-cell infiltration in the tumor, Eur J Immunol, vol.42, pp.1833-1875, 2012. ,
Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells, Cancer, vol.112, pp.863-75, 2008. ,
Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines, Clin Cancer Res, vol.17, pp.678-89, 2011. ,
Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression, Clin Cancer Res, vol.17, pp.6287-97, 2011. ,
A pilot trial of humanized anti-GD2 monoclonal antibody (hu14.18K322A) with chemotherapy and natural killer cells in children with recurrent/refractory neuroblastoma, Clin Cancer Res, 2017. ,
Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells, Biol Blood Marrow Transplant, 2017. ,
Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies, Frontiers in immunology, vol.7, p.492, 2016. ,
,
Allogeneic natural killer cells for refractory lymphoma, Cancer Immunol Immunother, vol.59, pp.1739-1783, 2010. ,
CD19-CAR trials, Cancer journal, vol.20, pp.112-120, 2014. ,
Relation between Acute GVHD and NK Cell Subset Reconstitution Following Allogeneic Stem Cell Transplantation, Frontiers in immunology, vol.7, p.595, 2016. ,
Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation, Blood, vol.125, pp.784-92, 2015. ,
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission, Blood, vol.120, pp.4317-4340, 2012. ,
Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma, Clin Cancer Res, vol.22, pp.5211-5233, 2016. ,
Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds, Blood, vol.126, pp.50-60, 2015. ,